Development of molecular assays for the rapid and cost-effective determination of fluoroquinolone, macrolide and lincosamide susceptibility of Mycoplasma synoviae isolates : Assay development for the determination of antibiotic susceptibility of Mycoplasma synoviae by Bekő, Katinka et al.
RESEARCH ARTICLE
Development of molecular assays for the
rapid and cost-effective determination of
fluoroquinolone, macrolide and lincosamide
susceptibility of Mycoplasma synoviae isolates
Katinka Bekő1, Zsuzsa Kreizinger1, Cécile Yvon1, Orsolya Saller1, Salvatore CataniaID2,
Anneke Feberwee3, Miklós GyuraneczID
1,4*
1 Institute for Veterinary Medical Research, Centre for Agricultural Research, Budapest, Hungary, 2 Instituto
Zooprofilattico Sperimentale delle Venezie, Verona, Italy, 3 GD Animal Health Service, Deventer, The




Mycoplasma synoviae infection occurs worldwide, leading to considerable economic losses
in the chicken and turkey industry due to infectious synovitis, respiratory diseases and egg-
shell apex abnormalities. Control programs against M. synoviae infection are based on
eradication, vaccination and medication with antimicrobial agents. Prudent use of antibiotics
can be improved greatly by the determination of antibiotic susceptibility prior to the treat-
ment. However, the conventional broth or agar microdilution is very labor-intensive and
time-consuming method. Thus, there is an increasing need for rapid antimicrobial suscepti-
bility tests in order to guide antibiotic therapy more effectively. The aim of this study was to
develop mismatch amplification mutation assays (MAMAs) to detect resistance-associated
mutations in M. synoviae. M. synoviae strains with previously determined minimal inhibitory
concentrations (MICs) and whole genomes (n = 92) were used for target selection and
assay specification. For the evaluation of the developed assays, 20 clinical samples and an
additional 20 M. synoviae isolates derived from these specimens were also included in this
study. MIC values of these 20 isolates were determined by broth microdilution method. Five
MAMAs were designed to identify elevated MICs of fluoroquinolones, while three MAMAs
were developed to detect decreased susceptibility to macrolides and lincomycin. The sensi-
tivity of the MAMA tests varied between 102−104 template copy number/reaction depending
on the assay. Clinical samples showed identical genotype calls with the M. synoviae isolates
derived from the corresponding specimens in each case. Supporting the results of conven-
tional in vitro sensitivity tests, our approach provides a feasible tool for diagnostics. Rapidity,
robustness and cost-effectiveness are powerful advantages of the developed assays. Sup-
porting prudent antibiotic usage instead of empirical treatment, the use of this method can
reduce significantly the economic impact of M. synoviae in the poultry industry and decrease
bacterial resistance-related public health concerns.
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Introduction
Mycoplasma synoviae infection occurs worldwide, leading to infectious synovitis or respiratory
diseases in chickens and turkeys, and it can be related to eggshell apex abnormalities in chick-
ens as well. In the affected flocks reduced feed intake, weight gain, egg production and hatch-
ability can be observed, leading to great economic losses. Control programs against M.
synoviae infection are based on eradication, vaccination and medication with antimicrobial
agents [1].
Prudent use of antibiotics in the management of M. synoviae infection can be improved
greatly by the determination of antibiotic susceptibility prior to the treatment. Most common
method of antibiotic susceptibility testing is the determination of minimal inhibitory concen-
tration (MIC) values in vitro by broth or agar microdilution. However, interpretation of the
results is difficult, because neither standard breakpoints of susceptible, intermediate and resis-
tant categories to antimicrobial agents, nor internationally harmonized testing conditions
have been defined yet concerning avian Mycoplasma species. Moreover, the results of in vitro
antibiotic susceptibility tests can only predict the expected in vivo efficacy of the antibiotics
[2], and the microdilution tests are very labor-intensive and time-consuming methods, as they
require previous isolation and pure culture of the bacterium [3]. Thus, there is an increasing
need for rapid antimicrobial susceptibility tests in order to support the choice of the most
appropriate antibiotic therapy. Investigating the correlation between in vitro antibiotic suscep-
tibility and resistance-associated mutations can provide an alternative option, as the majority
of the resistance mechanisms are mediated by genetic alterations [4]. A rapid and cost-effective
method is the detection of resistance-associated mutations by molecular biological assays [5,
6].
Numerous mutations related to antibiotic-resistance have been already described in avian
mycoplasmas, including M. synoviae as well. Several studies suggest that the primary target of
fluoroquinolones in M. synoviae is the A subunit of the DNA topoisomerase IV enzyme
(ParC) [7–9]. Mutations at the nucleotide positions 253–265 (or 238–250 according to Escheri-
chia coli numbering) of the quinolone resistance-determining region (QRDR) can result in the
alterations of ParC at the amino acid positions 85–89 (or 80–84 according to E. coli number-
ing) [7–9]. Beside this hot spot region, potentially resistance-related mutations have been iden-
tified in the gyrA (G28A, A428G, A566G, T1360A, C1361A, G1651A), gyrB (C446T, C1247A,
G1250A), and parE (C260T) genes of M. synoviae isolates with higher MIC values for fluoro-
quinolones as well [7–9].
Mutations in the central loop of the domain V (peptidyl transferase region) of 23S rRNA
confer resistance to 50S inhibitors in many bacteria. In M. gallisepticum, mutations at nucleo-
tide positions 2057–2059 (according to E. coli numbering) of the 23S rRNA coding genes
(rrlA/B) can lead to a disruption of the rRNA structure, thus alterations in this area can prevent
the attachment of the antimicrobial agents to their binding site [10]. Mutations A2054G and
A2055G (or 2058 and 2059 according to E. coli numbering) have been previously associated
with decreased susceptibility for macrolides and lincomycin in M. synoviae as well [9, 11]. It
also has been described, that resistance to lincomycin and tilmicosin does not require the
A2054G mutation in both rrl genes in M. synoviae, as the presence of this mutation only in the
rrlA or rrlB gene is enough to increase the MIC values of these antibiotics [9, 11].
Non-synonymous mutations of the rplV gene A276C/T (or 270 according to E. coli num-
bering) described previously in M. synoviae strains by Lysnyansky et al. [11] were also found
to decrease the susceptibility for macrolides, especially in case of tilmicosin [9]. These single
nucleotide polymorphisms (SNPs) result in a glutamine-histidine amino acid change at the
position 92 (or 90 according to E. coli numbering) of the 50S ribosomal protein L22.
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In the recent years, several studies found high MIC values of macrolides and lincosamides
against M. synoviae isolates [11–13]. Susceptibility of M. synoviae isolates to fluoroquinolones
also decreased over the last few decades, which is particularly troublesome as the use of fluoro-
quinolones is critical in the therapy of humans as well [7, 8, 12, 13].
The aim of this study was to develop rapid and cost-effective molecular biological assays for
the detection of the most important fluoroquinolone, macrolide and lincosamide resistance-
associated mutations in M. synoviae.
Materials and methods
Sample processing
In the present study, DNA samples of 20 clinical specimens and 112 M. synoviae strains,
including the M. synoviae type strain NCTC 10124, the MS-H (Vaxsafe1MS, Bioproperties
Pty Ltd., Ringwood, Australia) and MS1 (Nobilis1MS Live, MSD Animal Health Hungary,
Budapest, Hungary) vaccine strains, 89 field isolates from previous studies [9, 12] and 20 M.
synoviae isolates derived from the 20 clinical specimens were investigated. Samples were col-
lected between 1982 and 2019, originated from 23 different countries, and were isolated from
tracheal swabs or lungs of chickens and turkeys. According to the written declaration (refer-
ence number: IVMR/2019/0027) of the Ethics Committee of the Institute for Veterinary Medi-
cal Research, Centre for Agricultural Research ethical approval was not required for the study
as the samples were taken during routine diagnostic examinations with the written consent of
the owner. The final study and the manuscript was submitted and approved in a written decla-
ration by the Ethics Committee of the Institute for Veterinary Medical Research, Centre for
Agricultural Research. Background information of the used M. synoviae strains and clinical
samples are provided in S1 Table.
M. synoviae culture was performed as described previously [9]. In brief, the collected sam-
ples were placed into liquid Frey’s media [14] (Sigma-Aldrich Inc., St. Louis, USA) and trans-
ported to the laboratory for incubation at 37˚C in an atmosphere of 5% CO2. Following color
change (red to yellow shift) of the phenol red due to the metabolic activity of mycoplasmas,
the culture was inoculated onto solid Frey’s media [14] (Sigma-Aldrich Inc.) and incubated at
37˚C in an atmosphere of 5% CO2 until visible colonies appeared. Filter cloning was per-
formed to gain pure cultures from the isolates. When it was possible, cultures were filter cloned
only once to minimize in vitro mutations of the isolates.
DNA extraction from 200 μl pure M. synoviae logarithmic-phase broth culture was per-
formed using the ReliaPrep™ gDNA Tissue Miniprep System (Promega Inc., Madison, USA)
according to the manufacturer’s instructions for Gram-negative bacteria. In order to confirm
M. synoviae positivity of the samples, DNAs were submitted to M. synoviae-specific polymer-
ase chain reaction (PCR) [15]. The presence of other, contaminant mycoplasmas (i.e. M. galli-
septicum) was investigated by a universal Mycoplasma PCR system targeting the 16S/23S
rRNA intergenic spacer region of Mollicutes [16]. The PCR products were subjected to Sanger
sequencing on an ABI Prism 3100 automated DNA sequencer (Applied Biosystems, Foster
City, USA) and sequences were submitted to Nucleotide BLAST search (http://www.ncbi.nlm.
nih.gov/BLAST).
The DNA samples of the clinical specimens (original broth (tracheal swabs or lung tissue
samples washed into Frey’s medium [14] (Sigma-Aldrich Inc.)) and FTA cards) were extracted
using the Qiamp DNA Mini kit (Qiagen Inc., Hilden, Germany) according to the manufactur-
er’s instructions. The M. synoviae positivity and the presence of other, contaminant mycoplas-
mas were investigated by the aforementioned PCRs [15, 16].
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Broth microdilution
Minimal inhibitory concentration (MIC) values of two fluoroquinolones (enrofloxacin and
difloxacin), three macrolides (tylosin, tilmicosin and tylvalosin) and a lincosamide (lincomy-
cin) against 92 M. synoviae strains were determined previously by broth microdilution method
[9, 12] according to the recommendation of Hannan [3]. In this study, an additional 20 M.
synoviae isolates derived from the 20 examined clinical samples were submitted to susceptibil-
ity testing.
The antibiotics originated from VETRANAL (Sigma-Aldrich Chemie GmbH., Taufkirchen,
Germany) except for tylvalosin (Aivlosin), which was purchased from ECO Animal Health
Ltd. (London, UK). The antibiotics were diluted and stored according to the recommendations
of Hannan [3]. Stock solutions of 1 mg/ml for fluoroquinolones were prepared in 0.1 M
NaOH, while stock solutions of 1 mg/ml for macrolides and lincomycin were prepared in ster-
ile distilled water and stored at -70˚C. Freshly prepared two-fold dilutions were used in each
microtest after checking the thawed antibiotic solutions for any visible changes in their consis-
tency. The examined concentration range of the antibiotics was 0.039–10 μg/ml for fluoro-
quinolones and 0.25–64 μg/ml for macrolides and lincomycin.
Accepted number of microorganisms for the MIC tests was 104−105 color changing unit
(CCU/ml). The duplicates of clinical isolates and the duplicate of the M. synoviae type strain
NCTC 10124 were tested on each plate. The reference strain was included in the tests to con-
firm the validity of the results. The microtiter plates were sealed with adhesive film and incu-
bated at a temperature of 37˚C. The MIC value against each isolate was defined as the lowest
concentration of the antibiotic that completely inhibited the growth in the broth, i.e. no color
change has been observed. The MICs were read daily and recorded as soon as the growth con-
trols changed color.
Elevated MIC values indicating decreased susceptibility of M. synoviae isolates were deter-
mined above 1.25 μg/ml for fluoroquinolones, 0.5 μg/ml for tylvalosin, 1 μg/ml for tylosin,
8 μg/ml for tilmicosin, and 2 μg/ml for lincomycin, based on our previous study [9].
Assay development
For the detection of SNPs related to decreased susceptibility of M. synoviae isolates for fluoro-
quinolones, macrolides and lincomycin, mismatch amplification mutation assays (MAMAs)
were designed. MAMA is a PCR-based technique used for SNP discrimination in many bacte-
ria [17]. In brief, the technique is based on SNP-specific primers, one being marked with an
additional 14–20 base pair (bp) long GC-clamp. The GC-clamp increases the melting tempera-
ture (Tm) of the amplicon, and this temperature shift can be easily detected in the presence of
intercalating fluorescent dye on a real-time PCR platform (melt-MAMA).
Target mutations were selected according to the results of our previous study [9] based on
their correlation with elevated MIC values. Besides, the targeted SNPs had to be surrounded
by conserved regions suitable for primer design.
Primers were designed by Geneious software version 10.2.3. (Biomatters Ltd., Auckland,
New Zealand) [18] based on the whole genome sequences (Sequence Read Archive (SRA)
accession numbers: PRJNA634246 and PRJNA634252; GenBank accession numbers:
CP011096 and KP704286) of the 92 previously examined M. synoviae strains [9]. Each primer
set consisted of a consensus reverse primer and two competing forward primers designed to
specifically target the resistance-related SNP. At the allele-specific 30 end of the competing
primers, a single antepenultimate destabilizing mismatch was inserted to enhance the discrim-
inative capacity of the assay. The primer specific for the resistance-related SNP at the 3’ end
was marked with an additional 14 bp long GC-clamp at the 5’ end. The primers were
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constructed to limit amplicon lengths of�120 bp. The general suitability of the designed
primer sets was calculated by using NetPrimer software (Premier Biosoft International, Palo
Alto, USA) (http://www.premierbiosoft.com/netprimer). The specificity of the primers was
analyzed in silico using Nucleotide BLAST search (http://www.ncbi.nlm.nih.gov/BLAST).
The melt-MAMA PCR mixture consisted of nuclease-free water, 2 μl 5X Colorless GoTaq
Flexi Buffer (Promega Inc.), 1 μl MgCl2 (25 mM; Promega Inc.), 0.3 μl dNTP (10 mM; Fer-
mentas, Waltham, USA), 0.5 μl EvaGreen (20X, Biotium Inc., Hayward, USA), 0.08 μl GoTaq
G2 Flexi DNA polymerase (5 U/μl; Promega Inc.), 1 μl target DNA solution and primers
according to Table 1 with a final volume of 10 μl. Thermocycling parameters were 95˚C for 10
minutes, followed by 35 cycles of 95˚C for 15 seconds and 60˚C for 1 minute. PCR products
were subjected to melt analysis using a dissociation protocol comprising 95˚C for 15 seconds,
followed by 0.3˚C incremental temperature ramping from 60˚C to 95˚C. The real-time PCRs
were performed using Applied Biosystems Step-One Plus real-time PCR system with StepOne
software version 2.3 (Thermo Fisher Scientific Inc., Waltham, USA). EvaGreen fluorescence
intensity was measured at 525 nm at each ramp interval and plotted against temperature.
Nuclease-free water was used as negative control in all PCR assays.
Table 1. Sequences of the designed primers and their volumes used in each assay.
Assay Primer namea Primer sequence
(5’-3’)
Primer volumeb
MAMA-MS- gyrA gyrA-H ggggcggggcggggCTAGAATGGCTAAAATTTCAACTGG 0.15
gyrA-L CTAGAATGGCTAAAATTTCAACGGA 0.15
gyrA-C CGGTTGAATCATAGTTATCGACAAA 0.15
MAMA-MS- gyrB gyrB-H ggggcggggcggggTTACAAAAGAAAAAAGGATTAGGTAACTA 0.15
gyrB-L TTACAAAAGAAAAAAGGATTAGGTAAATC 0.6
gyrB-C TTTTTACTTGAACAATCAGAAAGCTT 0.15
MAMA-MS- parC-1 parC-1-H ggggcggggcggggAAGTATCAYCCTCATGGAGACAT 0.15
parC-1-L AAGTATCAYCCTCATGGAGAAAC 0.6
parC-C AATATTCATTTTTCATCACTGCG 0.15
MAMA-MS- parC-2 parC-2-H ggggcggggcggggAAGTATCAYCCTCATGGAGCTG 0.15
parC-2-L AAGTATCAYCCTCATGGAGGTA 0.15
parC-C AATATTCATTTTTCATCACTGCG 0.15
MAMA-MS- parE parE-H ggggcggggcggggCAGTTGAAAAAGTYAAAGGTGAGTT 0.15
parE-L CAGTTGAAAAAGTYAAAGGTGATTC 0.15
parE-C TCCTGAGGTTTTATATGAATCAGAAG 0.15
MAMA-MS- rrl rrl-H ggggcggggcggggGGTACCCGCATCAAGACCAG 0.6
rrl-L GGTACCCGCATCAAGACAAA 0.15
rrl-C CACATGTTAGGCCAAATTTCAATA 0.15
MAMA-MS- rplV-1 rplV-H-1 ggggcggggcggggTTTAAAATTTCGTAAGCTCTTACG 0.3
rplV-L TTTAAAATTTCGTAAGCTCTTGCT 0.15
rplV-C ATGTAAATGAAGGTCCTACCTTAAA 0.15
MAMA-MS- rplV-2 rplV-H-2 ggggcggggcggggTTTAAAATTTCGTAAGCTCTTTCA 0.3
rplV-L TTTAAAATTTCGTAAGCTCTTGCT 0.15
rplV-C ATGTAAATGAAGGTCCTACCTTAAA 0.15
aH refers to: specific for the genotype characterized by high MIC values for certain antibiotics; L refers to: specific for the genotype characterized by low MIC values for
certain antibiotics; C refers to: consensus
bPrimer (10 pmol/μl) volume in 10 μl reaction mixture (μl)
https://doi.org/10.1371/journal.pone.0241647.t001
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Specification and evaluation of the assays
Specification of the designed MAMAs was performed on DNAs extracted from pure cultures
of the 92 previously examined M. synoviae strains [9]. Genotype calls of these strains (genotype
H: genotype characterized by high MIC values for certain antibiotics; genotype L: genotype
characterized by low MIC values for certain antibiotics; genotype Het: heterozygous concern-
ing nucleotide position 2054 of the rrl genes) were compared with their whole genome
sequences (SRA accession numbers: PRJNA634246 and PRJNA63425; GenBank accession
numbers: CP011096 and KP704286).
In order to test the sensitivity of the assays, tenfold dilutions of each genotype were used in
the range of 106−100 template copy number/μl. Template copy number was calculated with the
help of an online tool [19] (http://cels.uri.edu/gsc/cndna.html) based on the DNA concentra-
tion measured by Nanodrop 2000 Spectrophotometer (Thermo Fisher Scientific Inc.). The
lowest template copy number yielding melting temperature specific to the genotype was con-
sidered as the detection limit of each assay.
The specificity of the assays was tested using the following avian Mycoplasma species: M.
anatis (ATCC 25524), M. anseris (ATCC 49234), M. anserisalpingitidis (ATCC BAA-2147), M.
cloacale (ATCC 35276), M. columbinasale (ATCC 33549), M. columborale (ATCC 29258), M.
gallinaceum (ATCC 33550), M. gallinarum (ATCC 19708), M. gallopavonis (ATCC 33551), M.
iners (ATCC 19705), M. imitans (ATCC 51306), M. iowae (ATCC 33552), M. meleagridis
(NCTC 10153), and M. gallisepticum (ATCC 19610).
For further evaluation of the assays, the designed MAMA tests were challenged with the
DNAs of clinical specimens (n = 20) and M. synoviae isolates derived from these clinical sam-
ples (n = 20), and their genotype calls were compared to each other.
The false result rate of the tests was calculated for each examined antibiotic group. The tests
were considered to give a false result if the genotype assignment of the applied assays were not
in line with the MIC data of the tested strain, i.e. all of the assays resulted in melting curve spe-
cific for genotype L in isolates with elevated MIC value for at least one of the tested agents, or
at least one of the assays resulted in melting curve specific for genotype H (or Het in case of
the MAMA-MS-rrl) in strains with low MIC value for all of the tested agents.
Results
Two MAMAs were designed to detect the SNPs A253G and C254T of the parC gene, result-
ing in amino acid change at position 85 of the ParC, which is the most relevant alteration
concerning fluoroquinolone susceptibility of M. synoviae according to the results of our
previous study [9]. Three additional resistance-related mutations of the gyrA (A566G), gyrB
(C1247A) and parE (C260T) genes were also targeted based on their frequent occurrence
[9].
To identify M. synoviae isolates with decreased susceptibility for macrolides and lincomy-
cin, a MAMA was designed to detect the SNP at nucleotide position 2054 of the rrlA/B genes.
Besides, for the determination of macrolide susceptibility, the mutation A276C/T of the rplV
gene was also targeted by two assays.
During specification, genotype calls by the designed MAMAs were congruent with the
whole genome sequences for all DNAs isolated from pure cultures of M. synoviae strains,
except for the isolate MYCAV102, which was undetectable in five out of eight assays (S1
Table). The presented MAMAs clearly differentiated the two genotypes characteristic for M.
synoviae isolates with high (genotype H) and low (genotype L) MIC values for certain antibiot-
ics, based on their distinguishable peaks of melting curves (Table 2).
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Besides, the assay MAMA-MS-rrl was able to differentiate heterozygous samples as well:
bimodal melting peak at the specific melting temperatures indicated the presence of both
nucleotides (A and G) at the position 2054 of the rrlA/B genes (genotype Het) (Fig 1).
It is important to mention, that isolates which show genotype H with the assay
MAMA-MS-parC-2 (i.e. carrying the SNP A253G) cannot be investigated with the assay
MAMA-MS-parC-1, as the SNP is at the penultimate position on the binding site of the for-
ward primers parC-1-H and parC-1-L. Thus, as expected, samples MYCS-17, MYCS-20 and
MYCS-21 were undetectable with MAMA-MS-parC-1 (S1 Table). Likewise, isolates which
showed genotype H with the assay MAMA-MS-rplV-1 (MYCS-79, MYCS-80) were undetect-
able with the assay MAMA-MS-rplV-2, and vice versa (MYCS-56, MYCS-57, MYCS-71,
MYCS-74), as these two assays targeted different nucleotides at the same position (A276C and
A276T in the rplV gene) (S1 Table).
Sizes and melting temperature ranges of the amplicons are listed in Table 2. Slight shifts of
the melting temperatures could be detected during the melt curve analysis of PCR amplicons
in the independent runs (maximum shift was 2.08˚C in MAMA-MS-parC-2), however, the
melt curve shapes and temperature differences remained unchanged. Negative controls gener-
ated non-specific products with melt-profiles differing from the profiles of the expected two
allelic states in the assays MAMA-MS-parC-2 (Tm 71.09˚C) and MAMA-MS-rplV-1 (Tm
84.42˚C) (Fig 2). In the rest of the assays, negative controls were not amplified (Table 2).
Although no-template negative control induced artifact-associated fluorescence in the
MAMA-MS-rrl assay (Fig 1A), no quantitation curve can be observed (Fig 1B).
The sensitivity of the melt-MAMA tests changed between 102−104 template copy number/
reaction depending on the assay (Table 2). Cross-reactions could be detected only in case of
Table 2. Results of MAMAs designed in this study.


















A566G Glu189Gly H 102 98 78.31–78.61 - -
L 102 84 73.99–74.59
MAMA-MS-
gyrB
C1247A Ser416Tyr H 102 82 77.86–78.32 - -
L 103 68 72.36–73.4
MAMA-MS-
parC-1
C254T Thr85Ile H 102 89 79.66–81.29 71.09 -
L 102 75 75.48–77.12
MAMA-MS-
parC-2
A253G Thr85Ala H 103 89 82.33–82.47 - -
L 103 75 75.33–77.41
MAMA-MS-
parE
C260T Ser87Phe H 102 118 81.58–82.18 - -





A2054G n.a. H 103 88 82.48–82.78 - M. anatis: 77.12 M.
anserisalpingitidis: 77.12 M.
gallinarum: 76.38
Het 102 74; 88 77.27–77.42;
82.42–82.57
L 103 74 77.12–77.72
MACROLIDES MAMA-MS-
rplV-1
A276C Gln90His H 103 85 79.35–79.5 84.42 -
L 104 71 74.44–75.63
MAMA-MS-
rplV-2
A276T Gln90His H 103 85 79.06–79.21 - -
L 104 71 74.59–75.63
SNP: single nucleotide polymorphism; AA subst.: amino acid substitution; Gt: genotype; bp: base pair; Tm: melting temperature; H: genotype characterized by high MIC
values; L: genotype characterized by low MIC values; Het: heterozygous genotype
https://doi.org/10.1371/journal.pone.0241647.t002
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the assay MAMA-MS-rrl with the following avian Mycoplasma species: M. anatis, M. anserisal-
pingitidis, M. gallinarum. Amplicons originating from the DNAs of these species showed melt-
ing temperatures around the average Tm of genotype L M. synoviae strains (77.3˚C) (Table 2).
In case of clinical specimens containing multiple Mycoplasma species [16], only one sample
(IDA 52W) had genotype L, which was inconsistent with the MIC data of the M. synoviae iso-
late derived from this sample (MYCAV703). Nevertheless, the clinical specimen (IDA 52W)
and the M. synoviae isolate (MYCAV703) showed similar melting temperature (77.27˚C and
77.42˚C) when investigated with the assay MAMA-MS-rrl.
The five MAMAs developed to determine susceptibility for fluoroquinolones were able to
discriminate 79.1% (68/86) of the examined M. synoviae isolates with elevated MIC values
Fig 1. Melt curve (A) and amplification plot (B) of the MAMA-MS-rrl assay developed for the determination of
macrolide and lincomycin susceptibility. The heterozygous MYCS-63 (genotype Het; purple line) displayed bimodal
melting peak at the specific melting temperatures of genotype L (MYCS-64; dark blue line; Tm 77.27˚C) and genotype
H (MYCS-65; red line; Tm 82.48˚C) M. synoviae isolates (A). The no-template negative control (light blue line) was
not amplified (B), but induced artifact-associated fluorescence (A). Fig 1A.: y-axis: derivative reporter, the negative
first-derivative of the normalized fluorescence generated by the reporter during PCR amplification; x-axis: temperature
melt curve; Fig 1B.: y-axis: difference between the normalized reporter (Rn) value (normalized fluorescence) of the
reaction and the Rn value of the baseline signal generated by the instrument; x-axis: number of cycles.
https://doi.org/10.1371/journal.pone.0241647.g001
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(>1.25 μg/ml) for enrofloxacin or difloxacin. The MAMA-MS-parC-1 targeting the SNP
C254T of the parC gene was able to detect 63 M. synoviae isolates with decreased fluoroquino-
lone susceptibility, while the other targeted mutations of the gyrA (A566G), gyrB (C1247A),
parC (A253G) and parE (C260T) genes identified 35, 31, 2 and 31 M. synoviae isolates with ele-
vated fluoroquinolone MIC values, respectively.
In case of lincomycin, molecular detection of the A2054G mutation in the rrlA/B genes
developed previously for the determination of the nucleotide at this position [9] was able to
identify 92.6% (25/27) of the examined M. synoviae isolates with elevated MIC values (>2 μg/
ml). It is worth to mention, that the MIC values (4 μg/ml) against both misclassified samples
(MYCS-72 and MYCAV703) were just above the limit.
Except for the same two samples (MYCS-72 and MYCAV703), the three MAMAs devel-
oped to determine susceptibility for macrolides were able to discriminate all examined M.
synoviae isolates (94.1%; 32/34) with elevated MIC values for tilmicosin, tylosin or tilvalosin
(>8 μg/ml,>1 μg/ml and >0.5 μg/ml, respectively). The MAMA-MS-rrl targeting the SNP
A2054G of the rrlA/B genes was able to detect 24 M. synoviae isolates with decreased macrolide
susceptibility, while the MAMA-MS-rplV-1 and -2 assays targeting the mutation A276C/T of
the rplV gene were able to detect 4–4 M. synoviae isolates with elevated macrolide MIC values.
False result rate of the PCR-based susceptibility tests was 2.9% (3/102) for macrolides and
lincomycin, and 14.8% (16/108) for fluoroquinolones, when pure cultures of M. synoviae iso-
lates were examined. Due to low DNA concentration (CT�30.04 by quantitative real-time
TaqMan PCR according to Raviv and Kleven [15]), four clinical samples (H1, H2, S4 and P2B)
were found to be under the detection limit of certain assays. Apart from this, clinical samples
showed identical genotype calls with the M. synoviae isolates derived from the corresponding
specimens by all of the designed MAMA tests. However, non-specific melting curves could be
Fig 2. Determination of macrolide susceptibility by the developed MAMA-MS-rplV-1 assay. Amplification
products of the genotype L (MYCS-78; dark blue line; Tm 75.48˚C) and genotype H (MYCS-79; red line; Tm 79.35˚C)
M. synoviae isolates showed specific melting temperatures. The no-template negative control (light blue line) displayed
melting peak at non-specific temperature (light blue line; Tm 84.42˚C). y-axis: derivative reporter, the negative first-
derivative of the normalized fluorescence generated by the reporter during PCR amplification; x-axis: temperature
melt curve.
https://doi.org/10.1371/journal.pone.0241647.g002
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observed beside the genotype-specific melting temperatures, resulting in bimodal melting
peaks in a few cases of clinical samples containing the DNA of M. synoviae only or multiple
Mycoplasma species as well [16] (Fig 3).
As no discrepancy could be observed between the genotype calls of M. synoviae isolates and
their corresponding clinical specimens, false result rate of the PCR-based susceptibility tests
has not been calculated specifically for clinical samples.
Discussion
Determination of antibiotic susceptibility in mycoplasmas by the conventional in vitro tech-
niques is very labor-intensive and time-consuming method, and the interpretation of the
results is difficult as well. Thus, there is an increasing need for reliable, rapid and convenient
antimicrobial susceptibility tests in order to support the choice of the most appropriate antibi-
otic therapy. In the current study, molecular biological assays were designed for the simulta-
neous detection of markers responsible for high MICs to certain antibiotics in M. synoviae.
Assays developed in the present study reliably discriminated M. synoviae genotypes charac-
terized by low or high MICs to the tested antibiotics by the melting temperatures of their
amplicons. However, the possible presence of unexplored mutations within the binding sites
of the primers or unknown variable mutation events may influence the reliability of the meth-
ods, and other resistance mechanisms may also complicate the determination of antibiotic sus-
ceptibility [20, 21].
Although most M. synoviae isolates with decreased fluoroquinolone susceptibility was
detected by the assay MAMA-MS-parC-1 targeting the SNP C254T of the parC gene, it is
advisable to investigate the presence of the other potentially resistance-related mutations of the
Fig 3. Determination of fluoroquinolone susceptibility by the developed MAMA-MS-gyrA assay. Amplification
products of the genotype L (MYCS-23; dark blue line; Tm 74.14˚C) and genotype H (MYCS-27; red line; Tm 78.31˚C)
M. synoviae isolates showed specific melting temperatures. Clinical sample H1 displayed bimodal curve with a peak at
the specific melting temperature of genotype L (Tm 74.02˚C) and an additional peak at non-specific temperature (Tm
81.28˚C). The no-template negative control (light blue line) was not amplified. y-axis: derivative reporter, the negative
first-derivative of the normalized fluorescence generated by the reporter during PCR amplification; x-axis: temperature
melt curve.
https://doi.org/10.1371/journal.pone.0241647.g003
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gyrA (A566G), gyrB (C1247A), parC (A253G) and parE (C260T) genes by the designed
MAMAs as well to further enhance the reliability of the results by simultaneous detection of
several mutations in different genes. Besides, performing all of these assays can provide infor-
mation about the prevalence of these resistance-related mutations, which can be later used for
reducing the number of the tests, or setting up an order according to their relevance. However,
as isolates which show genotype H with the assay MAMA-MS-parC-2 are found to be uncom-
mon, and they are undetectable with the assay MAMA-MS-parC-1, it is advisable to perform
the assay MAMA-MS-parC-2 just in the case when a sample cannot be amplified during the
MAMA-MS-parC-1 assay.
Most M. synoviae isolates with decreased macrolide and lincomycin susceptibility was
detected by the assay MAMA-MS-rrl targeting the SNP A2054G of the rrlA/B genes. Nonethe-
less, performing the assays MAMA-MS-rplV-1 and -2 targeting the mutation A276C/T of the
rplV gene beside the MAMA-MS-rrl is highly recommended for the determination of macro-
lide susceptibility, as the mutations A276C/T occurred exclusively in isolates lacking the SNP
A2054G of the rrl genes. However, as isolates which show genotype H with the assay
MAMA-MS-rplV-1 are undetectable with the assay MAMA-MS-rplV-2, and vice versa, it is
enough to apply one of these two assays at the first step, and perform the other one just in the
case when a sample cannot be amplified. Mutation A276T was found to be more frequent
according to the previous results of investigating whole genome sequenced M. synoviae strains
[9], while only the presence of the A276C was observed in the clinical sample-derived isolates
examined in this study. Thus, priorities of these two assays are hard to set for the time being.
The 20 examined clinical samples showed identical genotype calls with the 20 M. synoviae
isolates derived from the corresponding specimens by each assay which had sufficient sensitiv-
ity for the detection, including samples (n = 10) originating from birds with mixed infections
of different Mycoplasma species [16] as well. Thus, the assays could be considered applicable
on DNA samples extracted directly from clinical specimens. However, a limitation of this
method is that some of the developed assays do not have the sensitivity to test samples with
low specific DNA load (Ct >30 according to Raviv and Kleven [15]). Therefore, these molecu-
lar methods are most likely to be successful, when investigating clinical specimens collected
during the acute phase of the infection. In the later stages, the DNA concentration of the sam-
ples can decrease due to the reduced number of the bacteria. In these cases, isolation is recom-
mended instead of testing DNAs extracted directly from clinical samples. Cross-reactions with
other Mycoplasma species may occur as well in the case of assay MAMA-MS-rrl when testing
clinical specimens. As the amplicons of these species had melting temperatures around the
average Tm of genotype L M. synoviae strains (77.3˚C), excluding the presence of cross-react-
ing Mycoplasma species by a universal Mycoplasma PCR in the doubtful cases is recommended
for the reliable determination of macrolide and lincomycin susceptibility of M. synoviae
isolates.
The powerful advantages of the described method are rapidity, convenience and cost-effec-
tiveness. In the current study, all PCRs were designed with the same thermal profile allowing
their simultaneous application, and the developed MAMAs can be performed even on basic
real-time PCR machines. Thus, the application of our approach provides a feasible tool for
diagnostics.
Conclusion
Supporting the results of conventional in vitro sensitivity tests, the molecular biological assays
developed in this study can provide excellent assistance for the choice of the most appropriate
antibiotic therapy. The use of this molecular tool can contribute to achieve therapeutic success
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by reducing the detection time of antibiotic susceptibility, thereby significantly reduce eco-
nomic losses. Furthermore, early prediction of antibiotic efficacy by these assays can support
prudent antibiotic usage instead of empirical treatment, and decrease public health concerns
related to bacterial resistance by playing a proactive role in the reduction of antibiotics use.
Supporting information
S1 Table. Background information and MIC data of the used samples, and results of the
developed MAMA tests. A and B: Background information of the 92 M. synoviae strains pro-
vided by previous studies [9; 12] and results of fluoroquinolone (A), macrolide and lincomycin
(B) susceptibility determination by broth microdilution and the developed melt-MAMA tests.
C and D: Background information of the 20 clinical specimens and 20 clinical sample-derived
M. synoviae isolates examined in this study and results of fluoroquinolone (C), macrolide and
lincomycin (D) susceptibility determination by broth microdilution and the developed melt-
MAMA tests. MIC values were considered to be elevated above 1.25 μg/ml for enrofloxacin
and difloxacin; 8 μg/ml for tilmicosin; 1 μg/ml for tylosin; 0.5 μg/ml for tylvalosin; and 2 μg/ml
for lincomycin. Color codes indicating: elevated MIC (dark grey); low MIC (light grey); geno-
type assignment is congruent with the MIC data (green); genotype assignment is incongruent
with the MIC data, i.e. false result (yellow); congruency cannot be evaluated due to that the
sample was below detection limit in some of the assays (blue); excluded from the evaluation
due to missing MIC data (no color). PCR: polymerase chain reaction; CT: cycle threshold;
MAMA: mismatch amplification mutation assay; MIC: minimal inhibitory concentration; Gt:
genotype according to whole genome sequence; Tm: melting temperature; n.t.: not tested; n.a.:
not available; L: genotype characterized by low MIC values; H: genotype characterized by high
MIC values; Het: heterozygous genotype; NS: non-specific melting temperature; -: undetected;
�: expected to be undetectable by the assay
(XLSX)
Acknowledgments
The samples originating from the far eastern countries were kindly provided by Chris J.
Morrow.
Author Contributions
Funding acquisition: Zsuzsa Kreizinger, Miklós Gyuranecz.
Investigation: Katinka Bekő, Zsuzsa Kreizinger, Cécile Yvon, Orsolya Saller.
Methodology: Katinka Bekő.
Resources: Salvatore Catania, Anneke Feberwee, Miklós Gyuranecz.
Supervision: Zsuzsa Kreizinger, Miklós Gyuranecz.
Writing – original draft: Katinka Bekő.
Writing – review & editing: Zsuzsa Kreizinger, Salvatore Catania, Anneke Feberwee, Miklós
Gyuranecz.
References
1. Ferguson-Noel N, Noormohammadi AH. Mycoplasma synoviae infection. In: Swayne DE, editor. Dis-
eases of poultry. 13th ed. Hoboken: John Wiley & Sons Inc.; 2013. pp. 900–906.
PLOS ONE Assay development for the determination of antibiotic susceptibility of Mycoplasma synoviae
PLOS ONE | https://doi.org/10.1371/journal.pone.0241647 October 30, 2020 12 / 13
2. Hildebrand D. Immunology and prophylaxis associated with the use of a Mycoplasma gallisepticum bac-
terin in chickens. Clin Vet. 1985; 108: 89–94.
3. Hannan PCT. Guidelines and recommendations for antimicrobial minimum inhibitory concentration
(MIC) testing against veterinary Mycoplasma species. Vet Res. 2000; 31: 373–395. https://doi.org/10.
1051/vetres:2000100 PMID: 10958240
4. Sundsfjord A, Simonsen GS, Haldorsen BC, Haaheim H, Hjelmevoll SO, Littauer P, Dahl KH. Genetic
methods for detection of antimicrobial resistance. APMIS; 2004; 112: 815–837. https://doi.org/10.1111/
j.1600-0463.2004.apm11211-1208.x PMID: 15638839
5. Sulyok KM, Bekő K, Kreizinger Z, Wehmann E, Jerzsele Á, Rónai Z, Turcsányi I, Makrai L, Szeredi L,
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